Skip to main content
. 2020 Jan 6;111(2):561–570. doi: 10.1111/cas.14260

Figure 1.

Figure 1

Progression‐free survival (PFS) and overall survival (OS) of patients with BIM deletion‐positive epidermal growth factor receptor‐mutated non‐small cell lung cancer treated with gefitinib combined with vorinostat. Kaplan‐Meier curves for PFS (A) and OS (B) of 12 patients are shown. The 95% confidence intervals were calculated by using the Brookmeyer and Crowley method